Studying the Biotransformation of Phosphorothioate-Containing Oligonucleotide Drugs by LC-MS

  • Christophe Husser
  • Erich Koller
  • Andreas Brink
  • Simone SchadtEmail author
Part of the Methods in Molecular Biology book series (MIMB, volume 2036)


Across the pharmaceutical industry, there is increasing interest and need to investigate the biotransformation of oligonucleotide drugs. The method of choice is high-resolution mass spectrometry due to its unmet sensitivity and specificity.

Here, we describe a method developed and applied in our laboratory studying the biotransformation of phosphorothioate-containing oligonucleotide drugs. This method is based on capillary flow liquid chromatography with column switching coupled to high-resolution mass spectrometry.

Key words

Oligonucleotide biotransformation UPLC Column switching High resolution mass spectrometry All ion fragmentation 


  1. 1.
    Husser C, Brink A, Zell M, Muller MB, Koller E, Schadt S (2017) Identification of GalNAc-conjugated antisense oligonucleotide metabolites using an untargeted and generic approach based on high resolution mass spectrometry. Anal Chem 89(12):6821–6826. Scholar
  2. 2.
    Shemesh CS, Yu RZ, Gaus HJ, Greenlee S, Post N, Schmidt K, Migawa MT, Seth PP, Zanardi TA, Prakash TP, Swayze EE, Henry SP, Wang Y (2016) Elucidation of the biotransformation pathways of a Galnac3-conjugated antisense oligonucleotide in rats and monkeys. Mol Ther Nucleic Acids 5:e319. Scholar
  3. 3.
    Crooke ST (2008) Antisense drug technology: principles, strategies, and applications, 2nd edn. CRC Press, Boca RatonGoogle Scholar
  4. 4.
    Yu RZ, Kim TW, Hong A, Watanabe TA, Gaus HJ, Geary RS (2007) Cross-species pharmacokinetic comparison from mouse to man of a second-generation antisense oligonucleotide, ISIS 301012, targeting human apolipoprotein B-100. Drug Metab Dispos 35(3):460–468. Scholar
  5. 5.
    Geary RS, Norris D, Yu R, Bennett CF (2015) Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides. Adv Drug Deliv Rev 87:46–51. Scholar
  6. 6.
    Geary RS (2009) Antisense oligonucleotide pharmacokinetics and metabolism. Expert Opin Drug Metab Toxicol 5(4):381–391. Scholar
  7. 7.
    Yu RZ, Grundy JS, Geary RS (2013) Clinical pharmacokinetics of second generation antisense oligonucleotides. Expert Opin Drug Metab Toxicol 9(2):169–182. Scholar
  8. 8.
    Juliano RL (2016) The delivery of therapeutic oligonucleotides. Nucleic Acids Res 44(14):6518–6548. Scholar
  9. 9.
    Frieden M, Hansen HF, Koch T (2003) Nuclease stability of LNA oligonucleotides and LNA-DNA chimeras. Nucleosides Nucleotides Nucleic Acids 22(5-8):1041–1043. Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Christophe Husser
    • 1
  • Erich Koller
    • 1
  • Andreas Brink
    • 1
  • Simone Schadt
    • 1
    Email author
  1. 1.Roche Pharma Research and Early Development, Roche Innovation Center BaselF. Hoffmann-La Roche Ltd.BaselSwitzerland

Personalised recommendations